Revisiting Excitotoxicity in Traumatic Brain Injury:: From Bench to Bedside

Daniela Baracaldo-Santamaría; Daniel Felipe Ariza-Salamanca; María Gabriela Corrales-Hernández; Maria José Pachón-Londoño; Isabella Hernandez-Duarte; Carlos Alberto Calderon-Ospina

doi:10.3390/pharmaceutics14010152

Revisiting Excitotoxicity in Traumatic Brain Injury: From Bench to Bedside

Título traducido de la contribución: Reexaminando la excitotoxicidad en lesiones cerebrales traumáticas: : desde el laboratorio hasta la cabecera del paciente

Daniela Baracaldo-Santamaría, Daniel Felipe Ariza-Salamanca, María Gabriela Corrales-Hernández, Maria José Pachón-Londoño, Isabella Hernandez-Duarte, Carlos Alberto Calderon-Ospina

Producción científica: Contribución a una revista › Artículo de revisión › revisión exhaustiva

26 Citas (Scopus)

Resumen

La lesión cerebral traumática (TBI, por sus siglas en inglés) es una de las principales causas de morbilidad y mortalidad. Las consecuencias varían desde un deterioro cognitivo leve hasta la muerte y, sin importar la gravedad de las secuelas posteriores, representa una carga elevada para los pacientes afectados y para el sistema de atención médica. El trauma cerebral puede causar la muerte neuronal debido a fuerzas mecánicas que interrumpen la arquitectura celular, y otras consecuencias secundarias a través de mecanismos como la inflamación, el estrés oxidativo, la muerte celular programada y, lo más importante, la excitotoxicidad. Esta revisión tiene como objetivo proporcionar una comprensión integral de las numerosas vías clásicas y novedosas implicadas en el daño tisular tras una TBI. Resumimos las pruebas preclínicas de posibles intervenciones terapéuticas y describimos la evaluación clínica disponible de nuevos objetivos farmacológicos, como la vitamina B12 y el ifenprodil, entre otros.

Título traducido de la contribución	Reexaminando la excitotoxicidad en lesiones cerebrales traumáticas: : desde el laboratorio hasta la cabecera del paciente
Idioma original	Inglés estadounidense
Número de artículo	152
Publicación	Pharmaceutics
Volumen	14
N.º	1
DOI	https://doi.org/10.3390/pharmaceutics14010152
Estado	Publicada - ene. 2022

Áreas temáticas de ASJC Scopus

Ciencias farmacéuticas
Farmacología (médica)

ODS de las Naciones Unidas

Este resultado contribuye a los siguientes Objetivos de Desarrollo Sostenible

Acceder al documento

10.3390/pharmaceutics14010152

Otros archivos y enlaces

Citar esto

@article{18346883980b4f9caa0b2e9877d1229c,

title = "Revisiting Excitotoxicity in Traumatic Brain Injury:: From Bench to Bedside ",

abstract = "Traumatic brain injury (TBI) is one of the leading causes of morbidity and mortality. Consequences vary from mild cognitive impairment to death and, no matter the severity of subsequent sequelae, it represents a high burden for affected patients and for the health care system. Brain trauma can cause neuronal death through mechanical forces that disrupt cell architecture, and other secondary consequences through mechanisms such as inflammation, oxidative stress, programmed cell death, and, most importantly, excitotoxicity. This review aims to provide a comprehensive understanding of the many classical and novel pathways implicated in tissue damage following TBI. We summarize the preclinical evidence of potential therapeutic interventions and describe the available clinical evaluation of novel drug targets such as vitamin B12 and ifenprodil, among others.",

author = "Daniela Baracaldo-Santamar{\'i}a and Ariza-Salamanca, {Daniel Felipe} and Corrales-Hern{\'a}ndez, {Mar{\'i}a Gabriela} and Pach{\'o}n-Londo{\~n}o, {Maria Jos{\'e}} and Isabella Hernandez-Duarte and Calderon-Ospina, {Carlos Alberto}",

note = "Publisher Copyright: {\textcopyright} 2022 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2022",

month = jan,

doi = "10.3390/pharmaceutics14010152",

language = "English (US)",

volume = "14",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "1",

}

TY - JOUR

T1 - Revisiting Excitotoxicity in Traumatic Brain Injury:

T2 - From Bench to Bedside

AU - Baracaldo-Santamaría, Daniela

AU - Ariza-Salamanca, Daniel Felipe

AU - Corrales-Hernández, María Gabriela

AU - Pachón-Londoño, Maria José

AU - Hernandez-Duarte, Isabella

AU - Calderon-Ospina, Carlos Alberto

PY - 2022/1

Y1 - 2022/1

N2 - Traumatic brain injury (TBI) is one of the leading causes of morbidity and mortality. Consequences vary from mild cognitive impairment to death and, no matter the severity of subsequent sequelae, it represents a high burden for affected patients and for the health care system. Brain trauma can cause neuronal death through mechanical forces that disrupt cell architecture, and other secondary consequences through mechanisms such as inflammation, oxidative stress, programmed cell death, and, most importantly, excitotoxicity. This review aims to provide a comprehensive understanding of the many classical and novel pathways implicated in tissue damage following TBI. We summarize the preclinical evidence of potential therapeutic interventions and describe the available clinical evaluation of novel drug targets such as vitamin B12 and ifenprodil, among others.

AB - Traumatic brain injury (TBI) is one of the leading causes of morbidity and mortality. Consequences vary from mild cognitive impairment to death and, no matter the severity of subsequent sequelae, it represents a high burden for affected patients and for the health care system. Brain trauma can cause neuronal death through mechanical forces that disrupt cell architecture, and other secondary consequences through mechanisms such as inflammation, oxidative stress, programmed cell death, and, most importantly, excitotoxicity. This review aims to provide a comprehensive understanding of the many classical and novel pathways implicated in tissue damage following TBI. We summarize the preclinical evidence of potential therapeutic interventions and describe the available clinical evaluation of novel drug targets such as vitamin B12 and ifenprodil, among others.

UR - http://www.scopus.com/inward/record.url?scp=85122463641&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85122463641&partnerID=8YFLogxK

U2 - 10.3390/pharmaceutics14010152

DO - 10.3390/pharmaceutics14010152

M3 - Review article

C2 - 35057048

AN - SCOPUS:85122463641

SN - 1999-4923

VL - 14

JO - Pharmaceutics

JF - Pharmaceutics

IS - 1

M1 - 152

ER -